Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects

NCT01723748 NA COMPLETED

The treatment with SA still leaves some questions unanswered. Firstly, SA treatment often results in a concomitant suppression of the insulin secretion, which might lead to clinically significant glucose intolerance. Secondly, the traditional evaluation of disease activity by measuring circulating levels of GH and total IGF-I is not reliable enough Hypotheses: Treatment of acromegaly with SA versus surgery alone is associated with: * Glucose intolerance despite normalized insulin sensitivity * Modified peripheral GH activity in peripheral target organs assessed on molecular endpoints

Details

Lead sponsor	University of Aarhus
Phase	NA
Status	COMPLETED
Enrolment	18
Start date	2012-12
Completion	2015-05

Conditions

• Acromegaly
• Metabolic Diseases

Interventions

• genotropin

Primary outcomes

• Metabolism - including GH, IGF-I, FFA, glc and insulin. Concentration and AUC (area under the curve) — 3 years
  GH (ug/l), IGF-I (ug/l), FFA (mmol/l) , glc (mmol/l) and insulin (pmol/l)

Countries

Denmark